Tsai Chiaojung Jillian, Jackson Andrew, Setton Jeremy, Riaz Nadeem, McBride Sean, Leeman Jonathan, Kowalski Alex, Happersett Laura, Lee Nancy Y
All authors: Memorial Sloan Kettering Cancer Center, New York, NY.
JCO Clin Cancer Inform. 2017 Nov;1:1-7. doi: 10.1200/CCI.17.00070.
To develop personalized multivariate dose-response models for late dysphagia in patients with head and neck cancer treated in the modern era of combined chemotherapy with intensity-modulated radiation therapy.
The analysis included 424 patients (oropharyngeal cancer [n = 295] and nasopharyngeal, hypopharyngeal, or laryngeal cancer [n = 129]) who received definitive chemoradiation between January 2004 and April 2009. The superior, middle, and inferior pharyngeal constrictor muscles were contoured. We calculated generalized equivalent uniform dose (gEUD) for each and the total constrictor muscle volume, with the volume effect parameter a varying from log10 a = -1 to +1 in steps of 0.1. We used the National Cancer Institute Common Toxicity Criteria for Adverse Events (version 3.0) to grade late dysphagia and logistic regression to evaluate the correlation of gEUD( a) with grade 2 or higher (≥ G2) and grade 3 or higher (≥ G3) late dysphagia at each value of a.
Median follow-up was 33.3 months (range, 6 to 69 months). There were 41 cases (10%) of ≥ G2 dysphagia and 22 cases (5%) of ≥ G3 dysphagia. Mean doses to the total constrictor ranged from 30.1 to 85.7 Gy (median, 61.2 Gy). The predicted rate of ≥ G2 dysphagia increased by approximately 3.4% per Gy at the mean dose, for which the probability of ≥ G2 dysphagia is 50%. The threshold mean total constrictor doses that limited rates of ≥ G2 and ≥ G3 dysphagia to < 5% were < 58 Gy and < 61 Gy, respectively. Other significant factors in the multivariate predictive model included disease site, mean dose to total constrictor muscle, and patient age.
Incidences of both ≥ G2 and ≥ G3 dysphagia were dependent on the mean radiation dose to the total constrictor muscle volume, disease site, and patient age. Limiting the total volume of constrictor muscle to < 58 Gy could keep the predicted rate of ≥ G2 dysphagia to < 5%.
为在现代联合化疗与调强放射治疗时代接受治疗的头颈癌患者的晚期吞咽困难建立个性化多变量剂量反应模型。
分析纳入了2004年1月至2009年4月期间接受根治性放化疗的424例患者(口咽癌[n = 295]以及鼻咽、下咽或喉癌[n = 129])。对咽上缩肌、咽中缩肌和咽下缩肌进行轮廓勾画。我们计算了每块肌肉的广义等效均匀剂量(gEUD)以及总缩肌体积,体积效应参数a从log10 a = -1到+1,步长为0.1。我们使用美国国立癌症研究所不良事件通用毒性标准(第3.0版)对晚期吞咽困难进行分级,并采用逻辑回归评估在每个a值下gEUD(a)与2级或更高(≥ G2)以及3级或更高(≥ G3)晚期吞咽困难的相关性。
中位随访时间为33.3个月(范围6至69个月)。有41例(10%)≥ G2吞咽困难患者和22例(5%)≥ G3吞咽困难患者。总缩肌的平均剂量范围为30.1至85.7 Gy(中位剂量,61.2 Gy)。在平均剂量下,≥ G2吞咽困难的预测发生率每Gy增加约3.4%,此时≥ G2吞咽困难的概率为50%。将≥ G2和≥ G3吞咽困难发生率限制在< 5%的总缩肌阈值平均剂量分别< 58 Gy和< 61 Gy。多变量预测模型中的其他显著因素包括疾病部位、总缩肌的平均剂量以及患者年龄。
≥ G2和≥ G3吞咽困难的发生率均取决于总缩肌体积的平均放射剂量、疾病部位以及患者年龄。将缩肌总体积限制在< 58 Gy可使≥ G2吞咽困难的预测发生率保持在< 5%。